Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.
Also called NCT01475461
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 345 participants
- Sponsor
- Registry
-
NCT01475461 -
2011-004002-25
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Hungary, India, Philippines, Romania, Slovakia, South Africa, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01475461. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2017-01-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- PF-04937319 - 3mg
- Intervention (Drug)
- PF-04937319 - 20mg
- Intervention (Drug)
- PF-04937319 - 50mg
- Intervention (Drug)
- PF-04937319 - 100mg
- Intervention (Drug)
- Sitagliptin - 100mg
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01475461- Content hash
9c8f7a6f9c198a429024c24658188ea49f54ca80db9ef70769e54a57744e43bb